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IllustratIve case
Jason,	a	depressed	17-year-old,	is	brought	
in	by	his	mother,	who’s	worried	about	his	
mood	and	lack	of	motivation.	He	reports	
that	his	mood	has	“sunk”	over	the	last	
2	months.	His	mother	interjects	that	she	
suffers	from	depression	herself	and	that	
she’s	divorced	and	unable	to	compensate	
for	the	absence	of	Jason’s	father.	She	
also	says	that	her	2	older	sons,	both	of	
whom	Jason	is	close	to,	recently	moved	
out	of	state.	Further	questioning	reveals	
that	Jason	has	lost	interest	in	school,	
sports,	friends,	and	his	part-time	job;	he’s	
pessimistic	about	the	future	and	feels	
helpless	and	stuck.	Jason	avoids	going		
out	and	spends	hours	on	the	Internet.	
You	consider	prescribing	a	selective	
serotonin	reuptake	inhibitor	(SSrI),	but	
you’re	concerned	about	the	potential	
suicide	risk—a	risk	that’s	already	elevated	
for	teens	with	major	depressive	disorder	
(mDD).	Would	a	referral	to	a	therapist	be	
a	safer	choice?	Is	psychotherapy	alone	
sufficient?	What	type	of	therapy	is	best?	
Depressive disorders are common among adolescents and young adults, affecting nearly 1 in 4 by 
age 24.4 Most seek help from primary 
care physicians, who typically prescribe 
SSRIs.5 Yet only about one third of de-
pressed teens achieve complete remis-
sion with medication alone.1 For the 
two thirds who continue to have de-
pressive symptoms, the consequences 
can be severe. Depressive illness is asso-
ciated with family conflict, smoking and 
substance abuse, impaired functioning 
in school and in relationships, and in-
creased risk of suicide—the third lead-
ing cause of death in adolescents.6 
refer	adolescents	with	
moderate	to	severe	
depression	for	cognitive	
behavioral	therapy	(CbT)	to	
improve	their	outcomes.1-3
Strength	of	recommendation	
B:	Two	well-done	randomized	controlled	trials	(rCTs).
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z  Drugs, psychotherapy, 
or both? 
The Guidelines for Adolescent Depres-
sion in Primary Care (GLAD-PC), pub-
lished in November 2007, encourage 
primary care physicians to take a more 
active role in detecting and managing 
adolescent depression.7 GLAD-PC and 
the American Academy of Child and 
Adolescent Psychiatry recommend that 
teens with depressive illness receive psy-
chotherapy, either as primary treatment 
or in conjunction with antidepressants.7,8 
Until recently, however, that recom-
mendation lacked definitive evidence to 
support it.
stuDy summarIes 
z  2 studies explore 
combination approach
TADS (Treatment for Adolescents with 
Depression Study)2,3 and TORDIA 
(Treatment of Resistant Depression in 
Adolescents)1 are the only 2 randomized 
trials to address the role of CBT in com-
bination with antidepressants in treat-
ing this patient population. Both show a 
significant benefit when CBT is added to 
drug therapy.
TADS: Highest improvement  
rates with fluoxetine and CBT 
The TADS team studied 439 adolescents 
(ages 12 to 17 years) diagnosed with 
MDD. Patients were evaluated at con-
sent, baseline, and weeks 6, 12, 18, 30, 
and 36. Those who were already taking 
antidepressants were excluded, but con-
current therapy for attention-deficit hy-
peractivity disorder was permitted.
Participants were randomly assigned 
to 1 of the following 12-week treatment 
options: 
• Fluoxetine (10-40 mg/d) 
• CBT 
• Fluoxetine (10-40 mg/d) + CBT
• Placebo 
CBT consisted of 15 sessions over 12 
weeks, each lasting 50 to 60 minutes. In 
addition to individual sessions, 2 parental 
sessions and 1 to 3 family sessions were 
included. Primary outcome measures 
were the Clinical Global Impressions-Im-
provement Scale (CGI-I), which is based 
on a clinician’s overall assessment of the 
patient’s improvement; and the Chil-
dren’s Depression Rating Scale-Revised 
(CDRS-R), which is derived from parent 
and adolescent interviews. 
PURLs methodology
This study was selected and 
evaluated using FPIN’s Priority 
Updates from the Research 
Literature (PURL) Surveillance 
System methodology. The 
criteria and findings leading to 
the selection of this study as 
a PURL can be accessed at 
www.jfponline.com/purls. 
FigURE
Fluoxetine + CBT delivers biggest improvement  
for adolescents with depression
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Depressed adolescents
At 12 weeks, patients receiving 
fluoxetine and CBT demonstrated the 
highest rates of improvement: Seventy-
one percent (95% confidence interval 
[CI], 62%-80%) were “much” or “very 
much” improved, vs 60.6% (95% CI, 
51%-70%) of those on fluoxetine alone. 
In comparison, 43.2% (95% CI, 34%-
52%) of patients receiving CBT alone 
were much or very much improved at the 
12-week mark, and only 34.8% (95% 
CI, 26%-44%) of those on placebo. 
At 18 weeks, the medication/CBT 
combination remained superior to either 
psychotherapy or fluoxetine alone. By 
week 30, all 3 intervention groups con-
verged, and at 36 weeks there was virtu-
ally no difference in outcomes (FIGURE). 
cBt alone has protective effect. While 
CBT alone was not significantly better 
than placebo overall, it demonstrated a 
protective effect with regard to suicidal 
events (thoughts, threats, or attempts) 
compared to fluoxetine. Conversely, 
fluoxetine accelerated the rate of im-
provement in mood during the first 30 
weeks of treatment. 
TORDIA: How to help patients  
after failed treatment 
Brent and colleagues studied 334 patients 
between the ages of 12 and 18 years who 
were diagnosed with MDD but did not 
respond to initial SSRI therapy. After a 
4-week trial, they were reevaluated and 
tapered off the medication, then random-
ly assigned to 1 of the following treat-
ment groups for 12 weeks: 
• Switched to a new SSRI
•  Switched to venlafaxine (a selective 
serotonin-norepinephrine reuptake 
inhibitor)
• Switched to a new SSRI + CBT
• Switched to venlafaxine + CBT 
All patients were reevaluated at week 
12. Here, too, the CGI-I and CDRS-R 
were used for key outcome measures.
Adding CBT to a medication regi-
men was associated with an increased re-
sponse rate; choice of antidepressant was 
not. The groups receiving CBT were sig-
nificantly more likely to show improve-
ment compared to those who were not 
undergoing CBT (54.8% [95% CI, 47%-
62%] vs 40.5% [95% CI, 33%-48%], 
number needed to treat [NNT]=7). 
What’s neW?
z  An alternative that  
speeds recovery
These 2 studies confirm the value of CBT 
in treating moderate to severe major de-
pression in combination with antidepres-
sant therapy. TADS provides evidence 
of both a faster recovery trajectory and 
lower likelihood of suicidal events with 
combined treatment. While TORDIA 
does not demonstrate a quicker recovery 
in terms of depressed mood or a lower 
rate of suicidal events, it suggests that for 
adolescents who do not respond to an-
tidepressants, a referral to CBT will be 
more effective than a switch to a differ-
ent drug. 
caveats
z  Approach was not tested  
with mild depression 
Most adolescents who report depressive 
symptoms to primary care physicians ei-
ther do not meet the full criteria for ma-
jor depression or fall into the mild major 
depression range.9-11 Both of these studies 
enrolled only those with moderate to se-
vere MDD. 
There is evidence, however, that such 
an approach may not be necessary for 
teens with milder depression. Many earli-
er studies of psychotherapy alone vs con-
trol (wait list or observation) for patients 
with sub-threshold depressive disorders 
or mild major depression demonstrated 
that psychotherapy is effective in treat-
ing these less severe depressive states.7,12 
GLAD-PC recommends a 4- to 8-week 
trial of active monitoring for patients 
with mild MDD before initiating psycho-
therapy or medication. 2 
challenges to ImPlementatIon 
z Patient perceptions, stigma
There are 3 major barriers to imple-
Telling teens that 
“brain changes” 
cause depression 
may alleviate the 
stigma and  
self-blame 
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mentation: patient/parent resistance to 
psychotherapy, limited access to mental 
health specialists (lack of supply and in-
surance coverage limitations), and few 
quality standards for evidence-based psy-
chotherapeutic approaches in communi-
ty practice settings.13-15 Many adolescents 
have a negative view of therapy and feel 
stigmatized by a referral to a psychother-
apist. They may also have a well-devel-
oped rationale as to why such treatment 
would not work for them.16 
Physicians can help teens overcome 
these negative perceptions by giving 
them an opportunity to discuss their con-
cerns—and by clarifying any misconcep-
tions.17 The idea that “brain changes” 
cause depression has become popular 
in recent years,18 and may provide some 
relief to those who are troubled by the 
notion that they are somehow to blame 
for their depression.19 Presenting both 
antidepressant medication and psycho-
therapy as interventions that “change the 
way the brain manages mood” may be 
helpful in alleviating self-blame. 
Consider nontraditional  
approaches 
In areas with limited access to mental 
health specialists, nontraditional ap-
proaches may be needed. One such ap-
proach is to help patients arrange an ini-
tial interview with a psychotherapist, fol-
lowed by telephone counseling sessions. 
For patients 18 years or older, MoodGym 
(http://moodgym.anu.edu.au/welcome) is 
also an option. This free Internet site in-
corporates features of standardized CBT 
and interpersonal therapy, and has dem-
onstrated efficacy in RCTs of adults.20 
For those between the ages of 14 and 
21, CATCH-IT (http://catchit-public.bsd. 
uchicago.edu)21 is another Internet op-
tion. The site, which can be accessed by 
physicians and the general public, focuses 
on building competencies to reduce cur-
rent and future depressive symptoms. 
In addition, recommend self-help 
books. While there have been no studies 
of their value to adolescents, the book 
with the greatest evidence of efficacy in 
adults is “Feeling Good: The New Mood 
Therapy,” by David D. Burns.22
for your part… Before making re-
ferrals to mental health specialists, ask 
therapists whether they incorporate, and 
have been trained in, cognitive behavioral 
therapy. In addition, you can remain in-
volved by asking the psychotherapist for 
a written treatment plan and by encour-
aging adolescents (and their families) to 
fully adhere to it. n
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Cognitive behavioral therapy: It’s different from “talk” therapy 
Cognitive	behavioral	therapy	(CbT)	is	a	broad	group	of	therapies	that	differ	from	traditional	“talk”	
therapy	in	a	number	of	important	ways.	It	is	a	scientific,	evidence-based	form	of	psychotherapy	based	
on	the	belief	that	our	thoughts,	emotions,	and	behavior	are	linked	and	that	changing	the	way	we	think	
and	behave	will	positively	influence	our	emotions.	Key	features	of	CbT	include:
cognitive restructuring.	CbT	practitioners	help	patients	identify	irrational	beliefs	and	negative	auto-
matic	thoughts	and	“self-talk”	that	result	in	pessimistic	beliefs	and	negative	overgeneralizations,	and	
replace	them	with	more	realistic	and	positive	thoughts	and	beliefs.
Behavioral activation. Strategies	are	developed	to	create	pleasurable	experiences	to	overcome	the	
inertia	and	avoidance	behavior	associated	with	depression.	
Problem-solving collaboration. CbT	requires	an	active	collaboration	between	therapist	and	patient.	
Between-visit practice. “Homework”	is	an	expected	component	of	CbT,	with	patients	advised	to	
practice	the	skills	they	are	taught	and	to	work	on	specific	behavioral	or	cognitive	tasks	between	visits.
short duration. CbT,	which	typically	encompasses	12	to	15	sessions	over	a	12-week	period,	is	of	
much	shorter	duration	than	traditional	talk	therapy.
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